Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
Holding EXEL?
Track your performance easily
EXEL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.20 - $35.84
Previous Close$35.51
Volume1.76M
Average Volume (3M)2.09M
Market Cap
$10.14B
Enterprise Value$9.15B
Total Cash (Recent Filing)$1.19B
Total Debt (Recent Filing)$194.44M
Price to Earnings (P/E)22.6
Beta0.36
Next Earnings
Feb 11, 2025EPS Estimate
$0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.57
Shares Outstanding285,579,020
10 Day Avg. Volume3,062,188
30 Day Avg. Volume2,093,754
Standard Deviation0.11
R-Squared0.06
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)4.46
Price to Sales (P/S)4.77
Price to Cash Flow (P/CF)9.20
P/FCF Ratio9.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.39
Enterprise Value/Gross Profit5.20
Enterprise Value/Ebitda15.08
Forecast
1Y Price Target
$32.81Price Target Upside-8.35% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Exelixis News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceExelixis reported 3Q cabo revenues of $478.1M, ahead of FactSet consensus driven by increased cabo market share and new patient starts.
Intellectual PropertyThe IP decision upholding cabo's U.S. rights significantly changed the outlook for Exelixis.
Revenue GuidanceManagement raised and narrowed FY24 net product revenue and total revenue guidance by 5.6% and 7.4%, respectively, at the midpoint.
Bears Say
Clinical TrialsThe CONTACT-02 trial's final overall survival analysis did not reach statistical significance.
Intellectual PropertyIn the ANDA case between Exelixis and MSN Laboratories, the judge issued the ruling that the Malate Salt Patents is not infringed.
Revenue GrowthThere is uncertainty regarding the ability of the company to replace and grow revenues through and beyond the 2030 cabozantinib patent cliff.
---
Ownership Overview
2.97% Insiders
22.71% Mutual Funds
4.44% Other Institutional Investors
44.18% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $19.20 and its highest was $35.84 in the past 12 months.
What is Exelixis’s market cap?
Currently, no data Available
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Feb 11, 2025 which is in 95 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Oct 29, 2024. The company reported $0.4 earnings per share for the quarter, beating the consensus estimate of $0.339 by $0.061.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Overvalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is $0.38.
How many shares outstanding does Exelixis have?
Exelixis has 285,579,000 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.4 in its last earnings report, beating expectations of $0.339. Following the earnings report the stock price went up 12.913%.
Which hedge fund is a major shareholder of Exelixis?
Among the largest hedge funds holding Exelixis’s share is Farallon Capital Management, L.L.C.. It holds Exelixis’s shares valued at 609M.
---
Exelixis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.81 (-8.35% Downside)
$32.81 (-8.35% Downside)
Blogger Sentiment
Bullish
EXEL Sentiment 93%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 387.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.39%
12-Months-Change
Fundamentals
Return on Equity
20.20%
Trailing 12-Months
Asset Growth
-0.56%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
---
EXEL Company Deck
---
EXEL Earnings Call
Q3 2024
0:00 / 0:00
---
EXEL Revenue Breakdown
89.00% Net product revenues
9.76% License revenues
1.24% Collaboration services revenues
---
EXEL Stock 12 Month Forecast
Average Price Target
$32.81
▼(-8.35% Downside)
Technical Analysis
Best Analysts Covering EXEL
1 Year
1 Year Success Rate
15/15 ratings generated profit
1 Year Average Return
+34.47%
reiterated a buy rating 9 days ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +34.47% per trade.
---